A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically confirmed metastatic melanoma (Stage IV, American Joint Committee on
Cancer)

- Positive BRAF V600E mutation result determined by Cobas 4800 BRAF V600 Mutation Test

- Previously treated patients must have failed at least one prior treatment regimen; if
patients have received prior systemic treatments for metastatic melanoma, the time
elapsed from previous therapy must be >/= 28 days; patients must have recovered fully
from toxicities of all prior therapy

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Evaluable disease (measurable for disease progression according to RECIST criteria)

- Adequate hematological, renal and liver function

Exclusion Criteria:

- Active CNS lesions

- History of or known spinal cord compression or carcinomatous meningitis

- Anticipated or ongoing administration of anti-cancer therapies other than those
administered in this study

- Previous malignancy within the past 5 years except for basal or squamous cell
carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix

- Previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor

- Refractory nausea or vomiting, malabsorption, external biliary shunt, or history of
any type of gastrointestinal surgery that would preclude adequate absorption of study
drug